Durable Improvement in Generic and Fibroid-Specific Quality of Life in Women Treated with Transcervical Fibroid Ablation with the Sonata System After Three Years
Kelly Roy, James K Robinson, Kelly Roy, James K Robinson
Abstract
Objective: To determine quality-adjusted life years (QALYs) over 3 years after transcervical fibroid ablation (TFA) with the Sonata System.
Methods: The SONATA trial was a prospective multicenter interventional trial that assessed the safety and efficacy of TFA for treatment of women with symptomatic uterine fibroids. Change in generic health status was assessed with the EuroQol 5-Dimension questionnaire (0-1 scale). Fibroid-specific quality of life (QOL) was measured on a 0 to 100 scale with the health-related quality of life subscale of the Uterine Fibroid Symptom and Quality-of-Life (UFS-QOL). The number of QALYs gained relative to baseline and cumulative QALYs were calculated using the area under the curve at each follow-up visit over 3 years.
Results: Among 147 women receiving TFA, fibroid-specific QOL increased from 40 ± 21 at baseline to 84 ± 19 at 1 year and 83 ± 23 at 3 years (p < 0.001). Generic QOL increased from 0.72 ± 0.21 at baseline to 0.89 ± 0.12 at 1 year and 0.88 ± 0.16 at 3 years (p < 0.001). Over 3 years, TFA resulted in 1.24 ± 0.64 QALYs gained when using fibroid-specific health utility scores and 0.49 ± 0.61 QALYs gained when using generic health utility scores. Cumulative QALYs experienced at 3 years as a percentage of perfect health were 82% with fibroid-specific scores and 88% with generic health scores.
Conclusions: Women treated by TFA with the Sonata System for symptomatic uterine fibroids reported durable improvements in generic and fibroid-specific QOL, as well as clinically meaningful increases in QALYs over 3 years. Clinical Trials.gov ID: NCT02228174. (J GYNECOL SURG 38:143).
Keywords: QALY; leiomyoma; quality of life; quality-adjusted life year; transcervical fibroid ablation; uterine fibroid.
Conflict of interest statement
K.R. is a consultant to Gynesonics, Inc., and CrossBay Medical, Inc., J.K.R. reports no conflicts of interest.
© Kelly Roy et al. 2022; Published by Mary Ann Liebert, Inc.
Figures
References
- Williams VS, Jones G, Mauskopf J, et al. . Uterine fibroids: A review of health-related quality of life assessment. J Womens Health (Larchmt) 2006;15:818–829.
- Ulin M, Ali M, Chaudhry ZT, et al. . Uterine fibroids in menopause and perimenopause. Menopause 2020;27:238–242.
- Bradley LD, Pasic RP, Miller LE. Clinical performance of radiofrequency ablation for treatment of uterine fibroids: Systematic review and meta-analysis of prospective studies. J Laparoendosc Adv Surg Tech A 2019;29:1507–1517.
- Iversen H, Dueholm M. Radiofrequency thermal ablation for uterine myomas: Long-term clinical outcomes and reinterventions. J Minim Invasive Gynecol 2017;24:1020–1028.
- Lin L, Ma H, Wang J, et al. . Quality of life, adverse events, and reintervention outcomes after laparoscopic radiofrequency ablation for symptomatic uterine fibroids: A meta-analysis. J Minim Invasive Gynecol 2019;26:409–416.
- Toub DB. A new paradigm for uterine fibroid treatment: Transcervical, intrauterine sonography-guided radiofrequency ablation of uterine fibroids with the Sonata system. Curr Obstet Gynecol Rep 2017;6:67–73.
- Huirne J, Brooks E. Improvement in health utility after transcervical radiofrequency ablation of uterine fibroids with the sonata system: Health utility after radiofrequency ablation. Eur J Obstet Gynecol Reprod Biol 2018;224:175–180.
- Chudnoff S, Guido R, Roy K, et al. . Ultrasound-guided transcervical ablation of uterine leiomyomata. Obstet Gynecol 2019;133:13–22.
- Miller CE, Osman K. Transcervical radiofrequency ablation of symptomatic uterine fibroids: 2-year results of the SONATA pivotal trial. J Gynecol Surg 2019;35:345–349.
- Lukes A, Green M. Three-year results of the SONATA pivotal trial of transcervical fibroid ablation for symptomatic uterine myomata. J Gynecol Surg 2020;36:228–233.
- Rabin R, de Charro F. EQ-5D: A measure of health status from the EuroQol Group. Ann Med 2001;33:337–343.
- Harding G, Coyne KS, Thompson CL, et al. . The responsiveness of the uterine fibroid symptom and health-related quality of life questionnaire (UFS-QOL). Health Qual Life Outcomes 2008;6:99.
- Johnston BC, Patrick DL, Thorlund K, et al. . Patient-reported outcomes in meta-analyses-part 2: Methods for improving interpretability for decision-makers. Health Qual Life Outcomes 2013;11:211.
- Johnston BC, Thorlund K, Schunemann HJ, et al. . Improving the interpretation of quality of life evidence in meta-analyses: The application of minimal important difference units. Health Qual Life Outcomes 2010;8:116.
- Walters SJ, Brazier JE. Comparison of the minimally important difference for two health state utility measures: EQ-5D and SF-6D. Qual Life Res 2005;14:1523–1532.
- Matthews JN, Altman DG, Campbell MJ, et al. . Analysis of serial measurements in medical research. BMJ 1990;300:230–235.
- Phillips C. What is a QALY? What is …? series. 2009. . Accessed May 12, 2021.
- Greener M, Guest J. The models used for health economic analysis. Hosp Pharm 2006;13:45–47.
- Szende A, Janssen B, Cabases J. Self-Reported Population Health: An International Perspective based on EQ-5D. New York: Springer Open, 2014.
- Brolmann H, Bongers M, Garza-Leal JG, et al. . The FAST-EU trial: 12-month clinical outcomes of women after intrauterine sonography-guided transcervical radiofrequency ablation of uterine fibroids. Gynecol Surg 2016;13:27–35.
- You JH, Sahota DS, Yuen PM. Uterine artery embolization, hysterectomy, or myomectomy for symptomatic uterine fibroids: A cost-utility analysis. Fertil Steril 2009;91:580–588.
- Konopka JF, Lee YY, Su EP, et al. . Quality-adjusted life years after hip and knee arthroplasty: Health-related quality of life after 12,782 joint replacements. JB JS Open Access 2018;3:e0007.
- Rizzi CF, Ferraz MB, Poyares D, et al. . Quality-adjusted life-years gain and health status in patients with OSAS after one year of continuous positive airway pressure use. Sleep 2014;37:1963–1968.
- Brandao SMG, Hueb W, Ju YT, et al. . Utility and quality-adjusted life-years in coronary artery disease: Five-year follow-up of the MASS II trial. Medicine (Baltimore) 2017;96:e9113.
- Brooks E, Mihalov L, Delvadia D, et al. . The INSPIRE comparative cost study: 12-month health economic and clinical outcomes associated with hysterectomy, myomectomy, and treatment with the Sonata system. Clinicoecon Outcomes Res 2020;12:1–11.
Source: PubMed